Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Optimizing First-Line Management of Metastatic Hormone-Sensitive Prostate Cancer
The Advanced Prostate Cancer guidelines from the American Urological Association (AUA) and Society for Urologic Oncology provide a strong recommendation that patients with mHSPC should be treated with ADT in combination with an APRI or docetaxel. Although combination therapy improves survival of mHSPC patients and is recommended by national guidelines, evidence indicates that many patients do not receive this treatment approach.
Recognizing the importance of implementing first-line combination therapy in the treatment of mHSPC, the AUA, in collaboration with Astellas and Pfizer Oncology, conducted focus groups and interviews with healthcare providers in a variety of practice settings to understand current practice patterns and identify barriers and best practices to improve utilization of combination therapy for mHSPC.
This resource provides insights into best practices for those seeking to improve the treatment of patients with mHSPC.
advertisement
advertisement